Download Sample
Add to CartChronic Obstructive Pulmonary Disease (COPD) Market
By COPD Type;
Emphysema and Chronic BronchitisBy Treatment Type;
Drugs, Bronchodilator Monotherapy, Short-Acting Beta2-Agonists (SABAs), Long-Acting Beta2-Agonists (LABAs), Anti-Cholinergic Agents, Anti-Inflammatory Drugs, Oral and Inhaled Corticosteroids, Anti-Leukotrienes, Surgery, Lung Volume Reduction Surgery (LVRS), Lung Transplant, Bullectomy, and OthersBy Distribution Channel;
Hospital Pharmacies, Retail Pharmacies, and Online PharmaciesBy End User;
Hospitals and Clinics, Homecare Settings, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).Chronic Obstructive Pulmonary Disease (COPD) Market Overview
Chronic Obstructive Pulmonary Disease (COPD) Market (USD Million)
Chronic Obstructive Pulmonary Disease (COPD) Market was valued at USD 13,279.96 million in the year 2024. The size of this market is expected to increase to USD 17,593.49 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.1%.
Chronic Obstructive Pulmonary Disease (COPD) Market
*Market size in USD million
CAGR 4.1 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 4.1 % |
| Market Size (2024) | USD 13,279.96 Million |
| Market Size (2031) | USD 17,593.49 Million |
| Market Concentration | High |
| Report Pages | 364 |
Major Players
- Abbott Laboratories
- Almirall
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- Circassia Pharmaceuticals
- GlaxoSmithKline Plc
- Novartis AG
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Chronic Obstructive Pulmonary Disease (COPD) Market
Fragmented - Highly competitive market without dominant players
The Chronic Obstructive Pulmonary Disease (COPD) Market is growing as more patients require effective inhaled therapies—over 40% of new treatments focus on combined bronchodilators with corticosteroids to reduce flare-ups. Collaboration between pharma companies and lung specialists is accelerating treatment innovation. These improvements are fueling ongoing growth in therapeutic reach and patient outcomes.
Collaborative Innovation Spurs Connected Devices
Over 35% of companies are partnering to create smart inhalers and connected care platforms that track dose use and symptom patterns. These strategic alliances are resulting in technological advancements that support digital care and patient engagement. The result is expanding expansion into personalized and home-based management models.
Smart Monitoring Enables Proactive Interventions
Nearly 30% of COPD programs utilize apps and AI tools to monitor symptoms and suggest dosing changes before acute exacerbations. These solutions, supported by collaboration among clinicians and tech innovators, offer a compelling future outlook for early intervention and self-managed care.
Consolidation Strengthens Respiratory Care Networks
Roughly 38% of companies have merged to merge pharmaceutical and digital capabilities, creating unified care frameworks. These consolidations maintain innovation momentum and enhance growth and expansion through integrated product and service portfolios.
Chronic Obstructive Pulmonary Disease (COPD) Market Recent Developments
-
In January 2022, the first patient was enrolled in a phase 4 study comparing Yupelri (revefenacin) to Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The safety of these two approved once-daily COPD maintenance treatments would be assessed as well. Yupelri is a bronchodilator, a type of medication that relaxes and widens the lung airways, making breathing easier. It was developed by Theravance Biopharma and Mylan (now part of Viatris). It is available as an inhalable solution via a nebulizer, a small machine that turns liquid into a fine mist.
-
In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Mn. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD) Market Segment Analysis
In this report, the Chronic Obstructive Pulmonary Disease (COPD) Market has been segmented by COPD Type, Treatment Type, Distribution Channel, End User and Geography.
Chronic Obstructive Pulmonary Disease (COPD) Market, Segmentation by COPD Type
The Chronic Obstructive Pulmonary Disease (COPD) Market has been segmented by COPD Type into Emphysema and Chronic Bronchitis.
Emphysema
Emphysema accounts for approximately 55% of the Chronic Obstructive Pulmonary Disease (COPD) Market. It is characterized by the gradual destruction of alveoli in the lungs, leading to breathing difficulties. The demand for long-term treatment options like bronchodilators and oxygen therapy is high in this segment.
Chronic Bronchitis
Chronic Bronchitis holds around 45% of the market. This condition involves persistent inflammation of the bronchial tubes, causing mucus buildup and chronic coughing. Rising air pollution and tobacco use are key contributors to the prevalence of chronic bronchitis worldwide.
Chronic Obstructive Pulmonary Disease (COPD) Market, Segmentation by Treatment Type
The Chronic Obstructive Pulmonary Disease (COPD) Market has been segmented by Treatment Type into Drugs, Bronchodilator Monotherapy, Short-Acting Beta2-Agonists (SABAS), Long-Acting Beta2-Agonists (LABAS), Anti-Cholinergic Agents, Anti-Inflammatory Drugs, Oral And Inhaled Corticosteroids, Anti-Leukotrienes, Surgery, Lung Volume, Reduction Surgery (LVRS), Lung Transplant, Bullectomy and Others.
Drugs
Drugs dominate the COPD treatment market with over 65% market share. These include a wide range of pharmacological therapies aimed at managing symptoms and improving lung function in patients across all stages of the disease.
Bronchodilator Monotherapy
Bronchodilator monotherapy represents nearly 20% of the treatment landscape. It provides symptomatic relief by relaxing airway muscles and improving airflow, especially in patients with mild to moderate COPD.
Short-Acting Beta2-Agonists (SABAs)
SABAs hold about 10% of the market. These fast-acting agents offer quick symptom control, making them a critical component of rescue therapy during acute COPD exacerbations.
Long-Acting Beta2-Agonists (LABAs)
LABAs account for around 12% of the market. They provide extended bronchodilation and are commonly prescribed for maintenance therapy to reduce symptom frequency and severity.
Anti-Cholinergic Agents
Anti-cholinergic agents comprise approximately 15% of COPD therapies. These drugs block acetylcholine-induced bronchoconstriction and are used in both monotherapy and combination regimens.
Anti-Inflammatory Drugs
Anti-inflammatory drugs contribute around 8% to the market. These are used to reduce airway inflammation and prevent frequent exacerbations, especially in patients with a history of recurrent symptoms.
Oral and Inhaled Corticosteroids
This segment makes up about 18% of the treatment landscape. These corticosteroids play a vital role in managing moderate to severe COPD, particularly in patients with high eosinophil counts or overlapping asthma.
Anti-Leukotrienes
Anti-leukotrienes hold a smaller market share of around 5%. They are typically used in patients with coexisting asthmatic symptoms or in cases where other anti-inflammatory agents are less effective.
Surgery
Surgical interventions account for less than 2% of COPD treatments. They are reserved for patients with severe disease who do not respond well to pharmacological therapies.
Lung Volume Reduction Surgery (LVRS)
LVRS contributes marginally to the market. It improves lung efficiency by removing damaged portions of the lung, thereby enhancing breathing in select candidates with emphysema.
Lung Transplant
Lung transplant is a rare but critical intervention in end-stage COPD cases. It offers significant survival benefits for eligible patients, though limited donor availability restricts its usage.
Bullectomy
Bullectomy represents a niche surgical option. It involves removal of enlarged air sacs (bullae) that interfere with normal lung function, often improving breathing and quality of life.
Others
The “Others” segment includes emerging therapies and novel drug combinations currently under research. This area is expected to grow as newer, more effective treatment approaches are developed.
Chronic Obstructive Pulmonary Disease (COPD) Market, Segmentation by Distribution Channel
The Chronic Obstructive Pulmonary Disease (COPD) Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies
Hospital Pharmacies
Hospital pharmacies dominate the COPD market distribution with a share of around 50%. These outlets ensure immediate access to prescription medications for inpatients and those undergoing intensive or emergency COPD treatment within clinical settings.
Retail Pharmacies
Retail pharmacies contribute approximately 35% to the market. They offer widespread availability of maintenance medications for COPD and cater to outpatient needs, making them a convenient channel for chronic condition management.
Online Pharmacies
Online pharmacies are growing steadily, accounting for nearly 15% of the distribution share. The increasing adoption of digital healthcare platforms and the convenience of home delivery make this segment particularly appealing to elderly and remote patients.
Chronic Obstructive Pulmonary Disease (COPD) Market, Segmentation by End User
The Chronic Obstructive Pulmonary Disease (COPD) Market has been segmented by End User into Hospitals and Clinics, Homecare Settings and Others.
Hospitals and Clinics
Hospitals and clinics account for nearly 60% of the COPD market by end user. These facilities provide specialized respiratory care, access to emergency interventions and ongoing monitoring for patients with moderate to severe COPD conditions.
Homecare Settings
Homecare settings contribute around 30% to the market. With the rising preference for personalized and cost-effective care, especially among elderly patients, home-based management of COPD is gaining significant traction.
Others
The "Others" category, comprising rehabilitation centers and long-term care facilities, holds approximately 10% of the market. These settings focus on pulmonary rehabilitation, lifestyle support and chronic care solutions for advanced COPD cases.
Chronic Obstructive Pulmonary Disease (COPD) Market, Segmentation by Geography
In this report, the Chronic Obstructive Pulmonary Disease (COPD) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East, Africa & Latin America.
Regions and Countries Analyzed in this Report
Chronic Obstructive Pulmonary Disease (COPD) Market Share (%), by Geographical Region
North America
North America leads the COPD market with over 35% share, driven by high disease prevalence, strong healthcare infrastructure and widespread adoption of advanced respiratory therapies in the U.S. and Canada.
Europe
Europe contributes around 25% to the global market, supported by government-backed healthcare initiatives, rising aging population and increased awareness of COPD diagnosis and treatment.
Asia Pacific
Asia Pacific is witnessing rapid growth, accounting for approximately 20% of the market. Expanding healthcare access, rising pollution levels and increasing smoking rates in countries like China and India are key growth drivers.
Middle East
The Middle East represents a growing segment with 7% market share. Investments in healthcare infrastructure and a rise in chronic respiratory illnesses due to urbanization are influencing market expansion.
Africa & Latin America
Africa & Latin America collectively hold around 13% of the market. Limited access to healthcare and underdiagnosis of COPD are challenges, but ongoing public health efforts are helping to improve disease management.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Chronic Obstructive Pulmonary Disease (COPD) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Aging Population
- Advancements in Medical Research
- Increasing Awareness
-
Comprehensive Disease Management: Comprehensive disease management for Chronic Obstructive Pulmonary Disease (COPD) in the global market involves a multifaceted approach aimed at improving patient outcomes, enhancing quality of life, and reducing healthcare costs. This approach includes early diagnosis, patient education, regular monitoring, and personalized treatment plans. Early diagnosis is crucial as it allows for timely intervention, which can slow the disease's progression and mitigate symptoms. Patient education empowers individuals with COPD to manage their condition effectively through lifestyle changes, adherence to medication, and understanding symptom triggers.
The management strategy also emphasizes regular monitoring and follow-up, ensuring that treatment plans are adjusted as needed based on the patient's condition and response to therapy. This can involve the use of telemedicine and remote monitoring technologies, which have become increasingly important in recent years. Personalized treatment plans are tailored to the individual needs of each patient, often involving a combination of pharmacological treatments such as bronchodilators and corticosteroids, and non-pharmacological interventions like pulmonary rehabilitation and exercise programs.
The market for comprehensive COPD management is influenced by various factors including advances in medical technology, increasing prevalence of the disease, and a growing elderly population. Companies and healthcare providers are investing in innovative treatments and management tools to address the rising demand for effective COPD care. Additionally, there is a focus on improving access to care in underserved regions and integrating healthcare services to provide a more cohesive approach to managing COPD on a global scale. This comprehensive strategy aims to not only manage symptoms but also to enhance the overall well-being and longevity of patients living with COPD.
Restraints
- High Treatment Costs
- Limited Access to Healthcare
- Regulatory Challenges
-
Competition from Alternative Therapies: The global Chronic Obstructive Pulmonary Disease (COPD) market faces increasing competition from alternative therapies that aim to address the condition more effectively and with fewer side effects than traditional treatments. Alternative therapies, including non-pharmacological approaches like pulmonary rehabilitation, nutritional interventions, and holistic treatments such as acupuncture and herbal medicine, are gaining traction among patients and healthcare providers. These methods often focus on improving patients' quality of life, enhancing respiratory function, and managing symptoms through lifestyle changes and complementary practices rather than relying solely on pharmaceutical interventions.
Pulmonary rehabilitation, which includes exercise training, education, and behavioral changes, is a key alternative therapy showing significant promise. This approach helps improve the physical and emotional well-being of COPD patients, leading to reduced hospital admissions and healthcare costs. Nutritional support and dietary modifications are also becoming important, as proper nutrition can help manage weight and improve overall health, thereby alleviating some COPD symptoms. Additionally, interventions like acupuncture and herbal remedies are being explored for their potential to reduce inflammation, enhance lung function, and offer relief from symptoms, though more rigorous scientific studies are needed to fully validate their efficacy.
The rise of these alternative therapies is driven by a growing preference for holistic and integrative health approaches, as well as increasing evidence supporting their benefits. This shift poses a challenge to the traditional COPD pharmaceutical market, which has predominantly focused on inhalers, bronchodilators, and steroids. As more patients and clinicians look beyond conventional treatments for comprehensive COPD management strategies, pharmaceutical companies are being prompted to innovate and possibly integrate these alternative methods into their treatment protocols to remain competitive in the evolving healthcare landscape.
Opportunities
- Innovation in Therapeutics
- Multidisciplinary Care Approach
- Heightened COVID-19 Awareness
-
Holistic Disease Management: Holistic Disease Management (HDM) for Global Chronic Obstructive Pulmonary Disease (COPD) focuses on a comprehensive approach to care that addresses not only the physical symptoms of the disease but also the psychological, social, and lifestyle factors that contribute to its progression and management. This approach integrates various aspects of patient care, including pharmacological treatments, non-pharmacological interventions such as pulmonary rehabilitation and physical therapy, patient education, and lifestyle modifications like smoking cessation and nutrition. By considering the patient as a whole, HDM aims to improve overall quality of life, reduce hospitalizations, and decrease healthcare costs associated with COPD.
The global market for COPD management is evolving as healthcare providers and systems recognize the value of HDM. Advances in technology, such as telemedicine and remote monitoring devices, are facilitating more personalized and continuous care. These innovations enable healthcare professionals to monitor patients' conditions in real time, provide timely interventions, and support patients in managing their symptoms and treatment regimens more effectively. Additionally, there is an increasing emphasis on preventative care and early intervention, which are crucial for slowing disease progression and improving long-term outcomes.
Economic factors are also influencing the market for COPD management. The rising prevalence of COPD worldwide, particularly in low- and middle-income countries, is driving demand for cost-effective and accessible treatment options. Governments and healthcare organizations are investing in programs and initiatives that promote HDM as a sustainable approach to managing chronic diseases. Pharmaceutical companies are also developing new medications and therapies that complement holistic management strategies. Overall, the shift towards HDM in the global COPD market represents a paradigm change from traditional, symptom-focused care to a more integrated and patient-centered model.
Competitive Landscape Analysis
Key players in Global Chronic Obstructive Pulmonary Disease (COPD) Market include :
- Abbott Laboratories
- Almirall
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- Circassia Pharmaceuticals
- GlaxoSmithKline Plc
- Novartis AG
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By COPD Type
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By End User
- Market Snapshot, By Region
- Chronic Obstructive Pulmonary Disease (COPD) Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Aging Population
- Advancements in Medical Research
- Increasing Awareness
- Comprehensive Disease Management
- Restraints
- High Treatment Costs
- Limited Access to Healthcare
- Regulatory Challenges
- Competition from Alternative Therapies
- Opportunities
- Innovation in Therapeutics
- Multidisciplinary Care Approach
- Heightened COVID-19 Awareness
- Holistic Disease Management
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Chronic Obstructive Pulmonary Disease (COPD) Market, By COPD Type, 2021 - 2031 (USD Million)
- Emphysema
- Chronic Bronchitis
- Chronic Obstructive Pulmonary Disease (COPD) Market, By Treatment Type, 2021 - 2031 (USD Million)
- Drugs
- Bronchodilator Monotherapy
- Short-Acting Beta2-Agonists (SABAS)
- Long-Acting Beta2-Agonists (LABAS)
- Anti-Cholinergic Agents
- Anti-Inflammatory Drugs
- Oral And Inhaled Corticosteroids
- Anti-Leukotrienes
- Surgery
- Lung Volume Reduction Surgery (LVRS)
- Lung Transplant, Bullectomy
- Others
- Chronic Obstructive Pulmonary Disease (COPD) Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Chronic Obstructive Pulmonary Disease (COPD) Market, By End User, 2021 - 2031 (USD Million)
- Hospitals And Clinics
- Homecare Settings
- Others
- Chronic Obstructive Pulmonary Disease (COPD) Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Chronic Obstructive Pulmonary Disease (COPD) Market, By COPD Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Abbott Laboratories
- Almirall
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- Circassia Pharmaceuticals
- GlaxoSmithKline Plc
- Novartis AG
- Company Profiles
- Analyst Views
- Future Outlook of the Market